Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder
Although the primary endpoint was not met in the efficacy population, which included participants with mild depression, statistically significant improvements with navacaprant on depressive symptoms including anhedonia in the moderate-to-severe MDD subgroup, along with a favorable safety profile, support further study of navacaprant for the treatment of MDD.
Authors
- Jason X.‐J. Yuan (ORCID: https://orcid.org/0000-0002-0685-4862)
- Sanjay J. Mathew (ORCID: https://orcid.org/0000-0002-2715-6641)
- Michael Gold (ORCID: https://orcid.org/0000-0002-4410-1669)
- Bill Aurora
- Andrew J. Cutler (ORCID: https://orcid.org/0000-0001-5800-0378)
- Nicole C. Visitacion
Institutions
- Baylor College of Medicine (US)
- SUNY Upstate Medical University (US)
- C4 Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1097/jcp.0000000000001967
- Citations
- 8
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 11.16
Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Purdue University
- Sunovion
- Neos Therapeutics
- Sage Therapeutics
- BlackThorn Therapeutics
- H. Lundbeck A/S